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ABSTRACT 
Objective: 
Though depression is prevalent in long-term breast cancer survivors (LTBCS; ≥5 years since 
diagnosis), it is underdiagnosed and undertreated. A better understanding of factors associated 
with depression could improve depression screening, treatment and prevention in this 
population. Our study aimed to assess the link between patient and doctor ratings of breast 
cosmetic outcomes, late radiotherapy toxicity, and depression in LTBCS. 
 
Methods:  
In all, 214 patients recruited from the ARCOSEIN study were assessed for late radiotherapy 
toxicity (using the LENT-SOMA scale) and patient and doctor ratings of breast cosmetic 
outcomes (mean=6.7 years since the end of treatment). We reassessed 120 of these patients 
for depression (HAD) during a second wave of long-term assessment (mean=8.1 years since 
the end of treatment). We used univariate analyses and polytomous logistic regression 
analyses to predict the HAD depression, which was defined as follows: normal: 0-7 points 
and significant depression: ≥8 points (8-10 points: possible depression; ≥11 points: probable 
depression). 
 
Results: 
The mean HAD depression score was 4.5 ± 3.6. 19.2% of our population had significant 
depression, 6.7% with probable depression and 12.5% with possible depression. Significant 
depression was not associated with late radiotherapy toxicity or initial cancer-related 
variables. Patients with probable depression reported worse cosmetic outcomes than 
nondepressed patients in terms of perceived breast largeness (p=.04), breast deformation 
(p=.02), and changes in skin pigmentation (p=.03). 
 
 
Conclusions:  
In LTBCS, depression seems to be more strongly associated with changes in some patients’ 
perceived breast cosmetic outcome than late treatment toxicity or initial cancer-related 
variables.  
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INTRODUCTION 
 
Breast cancer is the most common cancer among women worldwide, representing 23% 
of all cancers in this population [1]. The incidence of breast cancer is also high; it represents 
22.9% of all estimated new cancer cases per year [1]. Because of better breast cancer 
detection and treatment, the breast cancer survival rate has dramatically improved since the 
1980s, with current 5-year survival rates of 89% in the United States [2], 85% in France [3], 
and 82% in the United Kingdom [4]. As the population ages, the number of breast cancer 
survivors increases, as does the number of long-term breast cancer survivors (LTBCS) [6]. 
LTBCS is defined by the American Cancer Society as a person who is still alive 5 years after 
diagnosis [5].  
As the number of LTBCS increases in conjunction with better survival rates, the 
psychosocial outcomes (e.g., quality of life, depression, and anxiety) in this population have 
attracted clinical interest. Although most studies have reported that LTBCS experience an 
overall good quality of life [6–8], many survivors still experience substantial problems as a 
result of the cancer or its treatment [8]. Burgess et al. have reported a 15 % prevalence of 
depression, anxiety, or both in the fifth year after breast cancer diagnosis [9]. There is 
evidence that depression in patients with cancer is a major predictor of distress and decreased 
quality of life for patients and their spouses, parents or other caregivers [10]. Because 
depression is underdiagnosed by oncologists and undertreated in patients with cancer [11–13], 
a better understanding of depression-associated factors would help clinicians to better screen 
for depression in LTBCS. 
Many factors are related to psychological distress in women coping with breast cancer. 
These factors include facing a life-threatening illness, painful and impairing treatments, 
significant role changes and issues related to body image [14]. According to Helms et al. [14], 
the association between issues related to body image and psychological distress has been less 
studied than other factors. The concept of body image is multidimensional because it 
encompasses both perceptual and subjective components [15]. Body image can be defined as 
"the picture we have in our minds of the size, shape and form of our bodies; and to our 
feelings concerning these characteristics and our constituent body parts" [16]. The dimensions 
of body experiences are highly subjective and do not necessarily reflect objective reality [15]. 
According to previous body image research in psychology, body image disturbances may lead 
to depressive symptoms, poor self-esteem and social anxiety [14].  
After breast cancer, one aspect of body image might be investigated using assessment 
of breast cosmesis, which incorporates the total sum of the breast’s appearance after treatment 
and an esthetic judgement of the breast’s appearance [17]. Body image might be assessed 
using objective evaluation (i.e., physician assessed), which relates to physician perceptions of 
breast cosmetic result itself, and subjective evaluation (i.e., patient assessed), which depends 
on how this objective breast cosmetic result is perceived and felt by the patient [15,16,18]. 
One potential difference between objective and subjective body image ratings is that the latter 
depend on the concern about body image, which pertains how much the body image matters 
to the patients [19]. In breast cancer survivors, both objective and subjective body image 
evaluations are needed to assess breast cosmetic outcomes [18]. 
After breast-conserving surgery, which is considered the least disfiguring surgical 
option after breast cancer [20], the esthetic outcome varies widely, and patients and 
physicians report alterations in breast cosmetic outcomes [17,18,21]. Unsatisfactory cosmetic 
results following breast-conserving surgery may contribute to depression [14,22,23]. In a 
population of breast cancer patients with a mean follow-up of 3.3 years, Al Ghazzal et al. [23] 
found a significant association between depression and breast retraction, nipple deviation and 
the overall cosmetic outcome of the treated breast. However, in that study, the breast cosmesis 
evaluation was performed by physicians and not by patients. In a population with follow-up 
of 1 to 4 years after surgery, Waljee et al. [24] found that women with pronounced perceived 
breast asymmetry were more likely to exhibit depressive symptoms than women with minimal 
asymmetry. However, this study included patients with a maximum follow-up of 4 years, 
whereas breast cosmetic outcomes may vary until at least 5 years after treatment [18]. 
Moreover, this study did not also assess the physicians’ breast cosmetic outcome ratings. To 
our knowledge, no study has focused on the association between depression and the patient 
and physician evaluations of cosmetic outcomes in LTBCS.  
Following breast cancer, use of radiotherapy has also been hypothesized to impact 
long-term breast cosmetic outcome [25]. Indeed, radiotherapy can lead to a broad range of 
late toxicity effects (e.g., edema, fibrosis) [26], which are radiotherapy-related adverse effects 
occuring at least 6 months after radiotherapy completion. To our knowledge, no study has 
focused on the association between depression and late radiotherapy toxicity in LTBCS. 
 
Our cohort study aimed to assess the association between depression and the patient 
and doctor evaluations of breast cosmetic outcomes in LTBCS. We hypothesized that 
depression is associated with worse patients’ and doctors’ breast cosmetic outcome 
evaluations for the treated breast. As a secondary objective, our study also aimed to assess the 
link between late radiotherapy toxicity and long-term depression. We hypothesized that the 
existence of late radiotherapy toxicity leads to higher depression levels. 
 
METHODS 
Participants and procedures 
Potentially eligible participants were recruited from the ARCOSEIN study [27,28]. The 
ARCOSEIN study was a multicenter French trial of breast cancer patients. It was initiated in 
1996 and compared sequential treatment (chemotherapy followed by radiotherapy) with 
concurrent treatment (chemotherapy administered concurrently with radiotherapy) after 
breast-conserving surgery. The study found that the concurrent use of chemotherapy and 
radiotherapy was significantly associated with improved locoregional control rates, but it 
increased the incidence of late side effects and altered breast cosmesis [25,29]. 
The ARCOSEIN study (first assessment; T1) enrolled 716 patients with Stage I and II 
breast cancer who underwent breast-conserving surgery with axillary dissection between 
February 1996 and April 2000 [28]. The detailed chemotherapy and radiotherapy regimen 
used in the ARCOSEIN study has been described elsewhere [29]. 
In a second step of the study (second assessment; T2), all participants from the 5 larger 
institutions that participated in the ARCOSEIN study (297 patients from the French 
Radiotherapy departments of Tours, Avignon, Institut Curie-Paris, Besançon and Orleans) 
were invited by letter for a follow-up visit that focused on late toxicity and patient and doctor 
breast cosmesis assessments [25]. This visit was performed between July 2004 and April 2005 
by an independent radiation oncologist. Of the 297 patients eligible for this second study, 214 
(72%) agreed to participate. 
These 214 patients were potentially eligible for our study (third assessment; T3). We 
contacted these patients between October 2005 and December 2005 to ask them to participate 
to our study. Of the 214 potentially eligible patients, those who had no local recurrence or 
bilateral breast cancer or metastase(s) and returned completed questionnaires (i.e., no missing 
data for any sociodemographic characteristics, the Hospital Anxiety and Depression scale or 
the LENT-SOMA scale) were considered eligible. 
 
Measures 
Demographics and medical variables (T1 and T3 assessments) 
We obtained data, including age at the end of chemoradiotherapy treatment, time since the 
end of treatment, menopausal status, marital status and cancer-related variables at diagnosis 
(e.g., tumor stage, node status, tumor dimension and histological type) or during treatment 
(i.e., surgery type, concurrent or sequential administration of chemoradiotherapy, 
hormonotherapy), from the initial ARCOSEIN medical file (T1 assessment). Psychotropic 
drug use (anxiolytics or antidepressants) and psycho-oncological intervention rates 
(consultation with a psychiatrist or a psychologist) since the end of chemoradiotherapy 
treatment were retrospectively assessed (T3 assessment). 
 
Breast cosmetic outcomes and late treatment toxicity assessment (T2 assessment) 
Breast cosmetic outcomes were assessed by patients and doctors.  
The patients were asked to complete the questionnaire developed by Hoeller et al. 
[30]. This questionnaire asked the patients to rate their overall cosmetic satisfaction using a 5-
point Likert response scale ranging from 1 (“excellent”) to 5 (“very poor”). The patients were 
also asked to rate the difference between the treated and untreated breast in terms of scar 
visibility, change in skin pigmentation, breast largeness, breast deformation, breast size, 
breast firmness and nipple displacement. These questions employed a 5-point Likert response 
scale ranging from 1 (“none”) to 5 (“very much”). These latter 8 items were treated as 
individual items because the factor analysis and Cronbach’s internal consistency analysis did 
not support the theoretical grouping of these items into one, two or three subscales. 
The doctors assessed cosmetic outcomes using two items that compared the treated 
and the untreated breast in terms of overall cosmetic satisfaction (an item developed by 
Fehlauer et al. [31] and scored with a 5-point Likert scale ranging from 1 [“excellent”] to 5 
[“very poor”]) and scar visibility assessment (an item developed by Hoeller et al. [30] and 
ranging from 1 [“excellent”] to 5 [“very poor”]). To avoid bias, the physician in charge of the 
evaluation had no knowledge of the patient’s assessment and was blinded to the type of 
chemoradiotherapy used (i.e., a sequential or concurrent regimen). Although the factor 
analysis did support the theoretical grouping of these items into one subscale, we treated them 
as individual items because Cronbach’s internal consistency was poor (=0.58).   
 
The late toxicity assessment, which was blinded to treatment allocation (concurrent or 
sequential radiochemotherapy), was graded by an oncologist according to the LENT-SOMA 
scale and translated to French [32,33]. The LENT-SOMA scale assesses the following late 
toxicity symptoms: pain, edema, fibrosis, telangiectasia, arm lymphedema, atrophy or 
retraction and ulcer. The toxicity level for each of these symptoms was graded on a scale from 
0 to 4, with a higher grade indicating a higher level of late toxicity. In our study, toxicity was 
considered nonsignificant if it was graded 0 or 1 and significant if it was graded 2, 3 or 4. In a 
previous study by Toledano et al. [25], these criteria allowed for very good interobserver 
reliability. These items were treated as individual items because the Kuder-Richardson 
coefficient for internal consistency was poor (KR-20=.51). 
 
Long-term depression (T3 assessment) 
We assessed long-term depression severity using the Hospital Anxiety and Depression scale 
(HAD) [34]. The HAD is a 14-item self-rating scale that assesses the severity of depression 
and anxiety, with each dimension receiving between 0 and 21. The HAD has been widely 
used and validated in cancer populations [35], has proven to have good reliability and validity 
[36], and is useful for screening for depression in LTBCS [37]. According to Bjelland et al. 
[36], an optimal balance between sensitivity and specificity is achieved when depression is 
defined by a score of 8 or above. In our study, there was significant depression when the 
depression score was 8 or above. According to Zigmond & Snaith [34], scores of 11 or higher 
on the depression subscale indicate probable depression, scores between 8 and 10 indicate 
possible depression, and scores between 0 and 7 are considered normal. 
 
Statistical analysis 
For better clarity, statistical analyses we conducted were described in the 
corresponding subsections of the Results section. Analyses were conducted using the 
statistical packages StatView for Macintosh Version 5.0 (Abacus Concepts, SAS Institute, 
Cary, NC) and Systat 12 (Systat Software, San Jose, CA). All analyses were two-tailed. P 
values < .05 were considered statistically significant. 
 
Ethics 
The ARCOSEIN study was initially approved by each local institutional review board, and 
informed written consent was obtained from all patients. For our study, we obtained informed 
consent from each patient in accordance with the Helsinki declaration.  
 
RESULTS 
Participants  
Figure 1 presents the study flow chart. Of the 214 potentially eligible patients, 138 returned a 
questionnaire, and 120 of these participants met our inclusion criteria. 18 participants (13%) 
were excluded: 4 (2.9%) because of recurrence and 14 (10.1%) because of incomplete 
reporting. 
 
Sample characteristics 
The sociodemographic and clinical characteristics of the patients are presented in Table 1. All 
patients were LTBCS (the time since the end of chemoradiotherapy treatment ranged from 6.1 
to 11.0 years) and initially underwent breast-conserving surgery with axillary dissection. The 
patient and doctor ratings of breast cosmetic outcomes are presented in Table 2. 
The mean HAD depression score was 4.5±3.6. Significant depression was observed in 
19.2% (n=23) of the patients, including 6.7% with probable depression and 12.5% with 
possible depression. Of the patients who had significant depression, 61% (n=14) had used 
psychotropic treatment, and 35% (n=8) had consulted a psychiatrist or a psychologist since 
the end of chemoradiotherapy treatment.  
 
Factors associated with long-term depression  
We tested the association between socio-demographic, cancer-related variables, late treatment 
toxicity and depression status (i.e., significant depression or no depression) using the chi-
squared test, Fisher’s exact test, the Kruskal-Wallis test or the Mann-Whitney U-test, 
depending on the variables involved (i.e., proportions or means). Because the chi-squared test 
must be considered only approximate when tables are larger than 2 x 2 with expected 
frequencies lower than 5, analyses were also conducted with depression as a continuous 
variable (Kruskal-Wallis test) in these cases. 
 
 
Sociodemographic and cancer-related variables 
Significant depression was not associated with age (p=.29), menopausal status (p=.44), or 
marital status (p=.15). Long-term significant depression was not associated with any of the 
cancer-related variables at diagnosis or during treatment, including the following: time since 
treatment ended (p=.59), tumor stage at diagnosis (p=.11)
1
, node status (p=.67), tumor 
                                                 
1
 p=.24 for Kruskal-Wallis test 
dimension (p=.83), histological type (p=.25)
2
, surgery type (p=.30)
3
, concurrent or sequential 
administration of chemoradiotherapy (p=.12), or hormonotherapy (p=.83). 
 
Late treatment toxicity 
There was no link between significant depression and the report of at least one late toxicity 
symptom (p=.73). Depression was not associated with any of the significant late toxicity 
symptoms, including pain (p=.34), edema (p=.99), fibrosis (p=.99), telangiectasia (p=.99), 
arm lymphedema (p=.58), atrophy or retraction (p=.15) and ulcer. 
 
 
Breast cosmetic outcomes (Table 3) 
We examined the associations between patient and doctor ratings of breast cosmetic outcomes 
and depression using polytomous logistic regression analyses, depression being considered as 
a three-way categorical variable (i.e., probable depression, possible depression and no 
depression). All regression models included age, tumor stage at diagnosis, time since the end 
of treatment and marital status as covariates. No significant first-order interaction was 
identified. 
 
DISCUSSION  
In this study, which was conducted in LTBCS with an average follow-up of 8.1 years, patients 
with probable depression perceived their treated breasts to be larger, more deformed, and have 
worse skin pigmentation than nondepressed patients. We also found that late radiotherapy 
toxicity and initial cancer-related variables were not associated with long-term depression in 
LTBCS. 
To our knowledge, this study is the first to show a significant link between long-term 
depression and patient breast cosmetic outcomes in LTBCS. The fact that breast largeness, 
breast deformation and change in skin pigmentation were the measures most strongly 
correlated with depression is intriguing. Body image encompasses both perceptual and 
subjective components [15], and in this study, we hypothesize that the perception of a 
deformed or larger breast relates to both dimensions, whereas the other items that we assessed 
would relate only to the perceptual dimension. According to Carver et al. [19], body image is 
often thought of in terms of physical appearance; however, body image may also pertain to 
integrity, wholeness, and normal functioning. In this study, we hypothesize that depression is 
more related to alterations in body image integrity, wholeness and functioning than physical 
appearance. Because being single was also found to be an independent risk factor for 
depression, we also hypothesize that concerns about body image, which may be higher among 
single women, also account for the increased risk for depression. Further prospective studies 
are needed to test these hypotheses.  
These results are consistent with previous psychology research [14] and reports with 
shorter follow-up periods [23,24]. These data underscore the close relationship between body 
image alterations and long-term depression, which can occur more than 5 years after the 
breast cancer diagnosis and initial treatment. Because depression is associated with a 
systematic negative cognitive bias in information processing [38], we can assume that 
depressed individuals might respond negatively across all self-reported measures. Because 
depression is not associated with all items related to patient breast cosmesis, this hypothesis 
alone cannot explain all of our results. A different hypothesis may be proposed to explain 
these results. Waljee et al. [24] proposed that altered breast cosmesis could be a constant 
                                                 
2
 p=.36 for Kruskal-Wallis test 
3
 p=.61 for Kruskal-Wallis test 
reminder of the disease and treatment process that impairs psychological adjustment after 
treatment.  
Discrepancy between patient and doctors ratings is consistent with previous research 
[17] but intriguing. One explanation for this discrepancy might be that subjective ratings 
depend on concern about body image, whereas objective ratings do not. Patients with higher 
concern about body image might be at higher risk of discrepancy between objective and 
subjective body image ratings. Future studies should investigate the potential impact of 
concern about body image to explain this discrepancy. Our results also confirm that a 
combination of objective and subjective evaluations are needed to assess breast cosmetic 
outcome. 
In another important finding of our study, the LTBCS-related depression risk does not 
seem to be associated with late radiotherapy toxicity symptoms or with the initial 
chemoradiotherapy treatment type. Our results are consistent with previous studies conducted 
in short-term breast cancer survivors, which demonstrated that the link between depression 
and treatment toxicity was nonsignificant or inconsistent regarding chemotherapy or 
hormonotherapy [9,39–41]. Our results agree with previous studies regarding the absence of a 
link between long-term depression and initial cancer-related variables, such as tumor stage at 
diagnosis [40], tumor size, tumor histological type and node status [9]. Only the time since 
diagnosis was found to be inconsistently associated with long-term depression [40–43], and 
no link between these variables was found in our sample. The small range in time since 
diagnosis in our sample may explain this result. Previous studies support our results and tend 
to suggest that late treatment toxicity, initial chemoradiotherapy type and cancer-related 
variables have no or a minimal impact on late depression in LTBCS. These results are also 
consistent with early-stage breast cancer studies that found that objective cancer-related 
variables are not associated with depressive symptoms [44,45]. 
The 19.2% significant depression prevalence rate observed in our study is comparable 
to or slightly higher than the prevalence reported in previous LTBCS studies that used the 
same HAD thresholds [46–48]. To our knowledge, our study includes survivors with the 
longest reported mean follow-up (time since the end of treatment=8.1 years). Our study 
confirms that although depression is common among patients with LTBCS, the reported rates 
of psychotropic medication use and psycho-oncological intervention are particularly low in 
this population. These results are consistent with the fact that among patients with cancer, 
depression is underdiagnosed by oncologists and is undertreated [11–13], although effective 
psychotherapeutic and pharmacological interventions exist in this field [10,49]. To deliver 
appropriate psycho-oncological care for depression, a close collaboration between psychiatric 
or psycho-oncological teams and oncological teams is needed. 
Our study has some limitations. First, we assessed long-term depression using a self-
administered scale (the HAD), which was mainly designed to screen for, rather than diagnose, 
depression. Although the use of a concomitant structured psychiatric interview for depression 
would have been time consuming, it may have decreased the number of false positive or 
negative depression cases. To our knowledge, no study has assessed LTBCS-related 
depression with a structured interview using DSM-IV depression criteria. Our small sample 
size and the 56% participation rate limits the generalizability of our findings, though the 
participation rate was comparable to previous studies [40,47]. Breast cosmesis was not 
evaluated with depression, and the time between the two evaluations was one and a half years. 
Finally, we tested the association between depression and a large number of factors, thus 
increasing the risk for Type I errors (false positives). 
Despite these limitations, our study shows that LTBCS-related depression is 
associated with some patients’ perceptions of changes in cosmetic outcomes for the treated 
breast. We also show that depression in this population is not associated with late 
radiotherapy toxicity, initial chemoradiotherapy treatment type, or initial cancer-related 
variables. These results have two important practical implications. First, because depression is 
underdiagnosed [11–13], clinicians should pay attention to patients’ perceptions of breast 
cosmetic outcomes and subjective aspects of body image, particularly breast largeness, 
because those factors can help clinicians screen for depression in this population. Second, 
long-term depression seems to correlate more strongly with alterations in some patient-
perceived body image variables than initial cancer-related variables or treatment toxicity in 
LTBCS. If confirmed, early alterations in patient body image could be an important target for 
psychotherapeutic intervention. Further prospective and longitudinal studies are warranted to 
delve further into the issue of depression-associated factors for LTBCS. 
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 TABLES 
Table 1. Characteristics of our study population (n=120) 
     
  Mean (±SD)    
  Number of patients (%)   
     
     
Sociodemographic characteristics     
   Age at the end of treatment (years)  50.2 (±8.1)   
     
   Age at the time of our study (years)  58.3 (±8.2)   
     
   Time since the end of treatment (years)  8.1 (±1.3)   
     
   Menopausal status (yes)  54 (45%)   
     
   Marital status (at the end of treatment)     
      Married or in a relationship  92 (76.7%)   
      Single  28 (23.3%)   
     
Cancer-related variables     
   Tumor stage at diagnosis     
      T0  5 (4.2%)   
      T1  69 (57.5%)   
      T2  43 (35.8%)   
      T3  0 (0%)   
      T4  1 (0.8%)   
     
   Node status (positive)  79 (65.8%)   
     
   Tumor dimension (mm)  19.2 (±8.1)   
     
   Histological type     
      Ductal  90 (75%)   
      Lobular  18 (15%)   
      Other  12 (10%)   
     
Type of treatment     
   Surgery type     
      Tumorectomy  105 (88.2%)   
      Quadrantectomy  15 (12.6%)   
     
   Administration of chemoradiotherapy     
      Concurrent     61 (50.8%)   
      Sequential  59 (49.2%)   
     
   Hormonotherapy (yes)  55 (45.8%)   
     
Significant late toxicity symptoms     
   At least one toxicity symptom  63 (53%)   
     
   Pain  18 (15%)   
     
   Edema  1 (0.8%)   
     
   Fibrosis  17 (14.2%)   
     
   Telangiectasia  17 (14.2%)   
     
   Arm lymphedema  4 (3.3%)   
     
   Atrophy or retraction  42 (35%)   
     
   Ulcer  0   
     
  
 
 
 
Table 2. Patient and doctor ratings of breast cosmetic outcomes   
         
    n   S1 S2 S3 S4 S5 
         
Overall cosmetic Patients 120  33 (27.5%) 39 (32.5%) 40 (33.3%) 6 (5%) 2 (1.7%) 
satisfaction Doctors 120  8 (6.7%) 48 (40%) 29 (24.2%) 22 (18.3%) 13 (10.8%) 
         
Visibility of the scar Patients 119  23 (19.35%) 57 (47.9%) 23 (19.35%) 13 (10.9%) 3 (2.5%) 
 Doctors 120  25 (20.8%) 44 (36.7%) 30 (25%) 14 (11.7%) 7 (5.8%) 
         
Change in skin 
pigmentation Patients 118  80 (67.8%) 27 (22.9%) 9 (7.6%) 2 (1.7%) 0 
         
Breast deformed Patients 117  42 (35.9%) 49 (41.9%) 16 (13.6%) 9 (7.7%) 1 (0.9%) 
         
Breast larger Patients 116  76 (65.5%) 26 (22.4%) 13 (11.2%) 1 (0.9%) 0 
         
Breast smaller Patients 114  41 (36%) 43 (37.7%) 12 (10.5%) 15 (13.2%) 3 (2.6%) 
         
Breast firmness Patients 120  62 (51.7%) 32 (26.7%) 14 (11.7%) 11 (9.1%) 1 (0.8%) 
         
Nipple displacement Patients 113  81 (71.7%) 19 (16.8%) 7 (6.2%) 5 (4.4%) 1 (0.9%) 
         
         
For overall cosmetic satisfaction: Score 1 (S1)=excellent; S2=good; S3=satisfying; S4=bad; S5=very bad 
For all other dimensions: Score 1 (S1)=not at all; S2=a little; S3=moderate; S4=much; S5=very much 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Polytomous logistic regression analysis of significant depression predictors  
 
  
Estimate 
Standard 
error  Z  p-value 
             
        
Probable depression vs. no depression        
   Patient ratings of breast cosmetic outcomes        
      Overall cosmetic satisfaction*  -.66 .40  -1.65  .10 
        
      Visibility of the scar*  -.64 .37  -1.71  .09 
        
      Change in skin pigmentation*  -1.12 .50  -2.22  .03 
        
      Breast largeness*  -.98 .47  -2.07  .04 
        
      Breast deformation*  1.14 .49  -2.36  .02 
        
      Breast size  .03 .43  .07  .94 
        
      Breast firmness*  .10 .38  .25  .80 
        
      Nipple displacement*  -.25 .41  -.61  .54 
        
   Doctor ratings of breast cosmetic outcomes        
      Overall cosmetic satisfaction*  -.75 .36  -2.08  .04 
        
      Visibility of the scar*  -.62 .38  -1.61  .11 
        
Probable depression vs. possible depression        
   Patient ratings of breast cosmetic outcomes        
      Overall cosmetic satisfaction  -.57 .47  -1.21  .23 
        
      Visibility of the scar*  -.76 .46  -1.65  .10 
        
      Change in skin pigmentation*  -1.10 .62  -1.77  .08 
        
      Breast largeness*  -.45 .54  -.83  .40 
        
      Breast deformation*  -.88 .53  -1.65  .10 
        
      Breast size  .11 .48  .23  .82 
        
      Breast firmness  -.12 .47  -.25  .80 
        
      Nipple displacement*  -.29 .50  -.58  .56 
        
   Doctor ratings of breast cosmetic outcomes        
      Overall cosmetic satisfaction*  -.62 .42  -1.49  .14 
        
      Visibility of the scar*  -.34 .43  -.80  .43 
         
 
All logistic regression analyses were adjusted for age, tumor stage at diagnosis, time since the end of treatment 
and marital status.  
* indicates that the corresponding regression analysis also showed a significant and independent effect for 
being single without first-order interactions. 
 
FIGURES 
Figure 1. Study flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARCOSEIN initial population (T1 assessment) 
716 patients with Stage I to II breast cancer treated 
with breast-conserving surgery with axillary dissection 
Population of the five larger participating 
institutions to ARCOSEIN study 
297 patients 
 
Patients agreed to participate to a follow up visit that 
focused on late toxicity and cosmetic evaluation = 
eligible population (T2 assessment) 
214 patients 
 
Patients agreed to participate to our study  
(T3 assessment) 
138 patients 
 
Fully exploitable questionnaires (T3 assessment) 
120 patients 
 
